Tiffany Pecor

Seattle Children's Hospital — United States

Medicine · Health Sciences

10h-index340citations21works1.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(12), SARS-CoV-2 and COVID-19 Research(5), Immunotherapy and Immune Responses(5), Mycobacterium research and diagnosis(5), Immune Cell Function and Interaction(3)

Publications21 total

Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine
npj Vaccines·2025· 1 citedOpen Access
Characterizing TLR4 agonist EmT4™ as an anti-<i>Mycobacterium tuberculosis</i> vaccine adjuvant
ImmunoHorizons·2025· 1 citedOpen Access
Evaluation of host immune responses to Mycobacteriophage Fionnbharth by route of delivery
Virology Journal·2025· 4 citedOpen Access
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques
npj Antimicrobials and Resistance·2024· 2 citedOpen Access
Mucosal BCG delivery provides a spectrum of protection from different Mycobacterium tuberculosis strains across susceptible and resistant mouse backgrounds
Frontiers in Tuberculosis·2024Open Access
Upregulation of IFN-stimulated genes persists beyond the transitory broad immunologic changes of acute HIV-1 infection
iScience·2023· 27 citedOpen Access
Spike-specific T cells are enriched in breastmilk following SARS-CoV-2 mRNA vaccination
Mucosal Immunology·2023· 28 citedOpen Access
An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis
Vaccines·2023· 62 citedOpen Access
Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen
Tuberculosis·2022· 19 citedOpen Access
Characterizing in vivo loss of virulence of an HN878 Mycobacterium tuberculosis isolate from a genetic duplication event
Tuberculosis·2022· 2 citedOpen Access
Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations
Frontiers in Microbiology·2022· 15 citedOpen Access
RNA-based vaccine demonstrates prophylactic efficacy against <i>Mycobacterium tuberculosis</i> challenge in a mouse model
2022Open Access
Spike-specific T cells are enriched in breastmilk following SARS-CoV-2 mRNA vaccination
2021· 6 citedOpen Access
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples
Journal of Immunological Methods·2021· 29 citedOpen Access
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples
2021· 2 citedOpen Access
Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models
Scientific Reports·2021· 25 citedOpen Access
Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29
Antimicrobial Agents and Chemotherapy·2019· 60 citedOpen Access
Subunit vaccine candidate with adjuvant confers protection against clinical <i>Mycobacterium avium</i> in wild type and immunocompromised mouse models
The Journal of Immunology·2019
Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment
Vaccines·2018· 29 citedOpen Access
Use of GLA-nanoalum as an effective adjuvant for a therapeutic ID93 TB vaccine
The Journal of Immunology·2018
page 1 of 2Next →

Frequent Co-authors

Sasha E. Larsen(19), Rhea N. Coler(19), Susan L. Baldwin(15), Valerie A. Reese(13), Bryan J. Berube(6), Brendan K. Podell(6), Steven G. Reed(4), Jesse H. Erasmus(3), Jacob Archer(3), Bryan P. Brown(3), Brian Granger(3), Whitney E. Harrington(3), Hazem F. M. Abdelaal(3), Debora Ferede(3), Suhavi Kaur(3), Amit Kandahar(2), Fan‐Chi Hsu(2), Graham F. Hatfull(2), Evan Cross(2), Brittany D. Williams(2)